Ideaya Biosciences Inc. CEO Yujiro Hata told BioWorld Today that "you'd be hard pressed to find a more personalized-medicine approach to cancer" than synthetic lethality, and his firm hopes to build on proof of concept brought about by the approval of Astrazeneca plc's poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) in BRCA-mutated advanced ovarian cancer.